APTINYX INC (APTX) Stock Price, Forecast & Analysis
USA - NASDAQ:APTX - US03836N1037 - Common Stock
APTX Key Statistics, Chart & Performance
The current stock price of APTX is 0.061 USD. In the past month the price decreased by -53.29%. In the past year, price decreased by -89.72%.
APTX Latest News, Press Relases and Analysis
APTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About APTX
Company Profile
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
Company Info
APTINYX INC
1801 Maple Ave Ste 4300
Evanston ILLINOIS 60201 US
CEO: Norbert G. Riedel
Employees: 12
Phone: 18478710377.0
APTINYX INC / APTX FAQ
Can you describe the business of APTINYX INC?
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
Can you provide the latest stock price for APTINYX INC?
The current stock price of APTX is 0.061 USD. The price decreased by -39% in the last trading session.
Does APTX stock pay dividends?
APTX does not pay a dividend.
What is the ChartMill rating of APTINYX INC stock?
APTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists APTX stock?
APTX stock is listed on the Nasdaq exchange.
Is APTINYX INC (APTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APTX.
What is the market capitalization of APTX stock?
APTINYX INC (APTX) has a market capitalization of 4.13M USD. This makes APTX a Nano Cap stock.
APTX Technical Analysis
APTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APTX. While APTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
APTX Financial Highlights
Over the last trailing twelve months APTX reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 13.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.58 |
APTX Forecast & Estimates
8 analysts have analysed APTX and the average price target is 0.51 USD. This implies a price increase of 736.07% is expected in the next year compared to the current price of 0.061.
For the next year, analysts expect an EPS growth of 50.06% and a revenue growth -100% for APTX